Interview - Johnson & Johnson Breathes New Life Into Infectious Diseases


When Johnson & Johnson (NYSE:JNJ) highlighted 12 potential blockbusters from its pipeline in May there were a few on the list that raised eyebrows. Two of these - the flu project pimodivir and the respiratory syncytial virus candidate lumicitabine - are in a sector where the company is not currently well known: infectious diseases.

"It's a new area to J&J to a certain extent," Julian Symons, head of Janssen's respiratory infections division, tells EP Vantage. "But it's a huge unmet medical need, and all our medicines are first-in-class agents." J&J still has a long way to go, however, before it can show that these assets live up to its lofty expectations.


It's on us. Share your news here.

Submit your stories and articles to citybizlist today.